Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19476026 | 0.84 | KDM4E (0.63) | ALDH1A1KDM4EGAASMN1; SMN2ABCG2 | |
| SCHEMBL17469677 | 0.83 | ELANE (0.39) | ALDH1A1CYP3A4CYP1A2ACHEMEN1 | |
| SCHEMBL19476168 | 0.82 | HTR1A (0.40) | ACHECA1KDM4EGAASMN1; SMN2 | |
| SCHEMBL19175981 | 0.81 | PPARG (0.44) | ALDH1A1CYP3A4CYP1A2ACHECA1 | |
| SCHEMBL19476025 | 0.76 | PARP10 (0.47) | ALDH1A1CYP3A4CYP1A2MEN1KMT2A | |
| SCHEMBL2060122 | 0.76 | KDM4E (0.71) | ALDH1A1CYP3A4CYP1A2ACHEMEN1 | |
| SCHEMBL7604955 | 0.76 | CA9 (0.43) | ALDH1A1CYP3A4CYP1A2MEN1KMT2A | |
| SCHEMBL29434781 | 0.76 | KDM4E (0.71) | ALDH1A1CYP3A4CYP1A2ACHEMEN1 | |
| SCHEMBL19476057 | 0.75 | MAOB (0.48) | MAOB | |
| SCHEMBL21526732 | 0.74 | ALDH1A1 (0.59) | ALDH1A1CYP3A4CYP1A2ACHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2021-11-25 | — | — | US | disclosed |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2020-11-12 | — | — | US | disclosed |
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | disclosed |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2016-04-21 | — | — | US | disclosed |
| US-9199990-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2015-12-01 | — | — | US | disclosed |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (US) | 2015-03-12 | — | — | US | disclosed |
| EP-2314295-B1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX INC (CA) | 2015-01-28 | — | — | EP | disclosed |
| US-8889698-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2014-11-18 | — | — | US | disclosed |
| WO-2013156869-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
| EP-1909788-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007016525-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2007-02-08 | — | — | WO | disclosed |
| US-20050043411-A1 | Process for preparing homophthalate derivatives | TJGEL, LLC | 2005-02-24 | — | — | US | disclosed |
| US-6797838-B2 | Process for preparing homophthalate derivatives | ILEX PRODUCTS, INC. | 2004-09-28 | — | — | US | disclosed |
| EP-1404662-A2 | PROCESS FOR PREPARING ISOCOUMARINS | Ilex Products, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040024240-A1 | Process for preparing homophthalate derivatives | GENZYME CORPORATION | 2004-02-05 | — | — | US | disclosed |
| US-6664401-B2 | Reacting a isochroman-1,3-dione with a carbonyl compound whose carbonyl group is substituted with an acyl activating group, in the presence of a base and a solvent; use making anticancer agents for example | ILEX PRODUCTS, INC. | 2003-12-16 | — | — | US | disclosed |
| US-20030105340-A1 | Process for preparing isocoumarins | GENZYME CORPORATION | 2003-06-05 | — | — | US | disclosed |
| WO-2003004486-A2 | PROCESS FOR PREPARING ISOCOUMARINS | ILEX PRODUCTS, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885CYP3A4 2473/4885CYP1A2 1243/4885 |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BRD4, BMI1, BRPF3 | ALDH1A1 4671/4885CYP3A4 4762/4885CYP1A2 4781/4885 |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885CYP3A4 2473/4885CYP1A2 1243/4885 |
| US-20030105340-A1 | Process for preparing isocoumarins | DHPS, IDH2, IDH1 | ALDH1A1 1178/4885CYP3A4 32/4885CYP1A2 106/4885 |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885CYP3A4 2473/4885CYP1A2 1243/4885 |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885CYP3A4 2473/4885CYP1A2 1243/4885 |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885CYP3A4 2473/4885CYP1A2 1243/4885 |
| US-20050043411-A1 | Process for preparing homophthalate derivatives | HPD, HAAO, PAH | ALDH1A1 669/4885CYP3A4 9/4885CYP1A2 99/4885 |
| US-20040024240-A1 | Process for preparing homophthalate derivatives | HPD, HAAO, PAH | ALDH1A1 669/4885CYP3A4 9/4885CYP1A2 99/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | ALDH1A1 1784/4885CYP3A4 1991/4885CYP1A2 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.